← Leaderboards
Robert C Bast
University Of Texas Md Anderson Can Ctr
$38,086,401
Attributed
$44,031,540
Total exposure
24
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$91,819,725 · 27
By mechanism
P50$57,743,399 · 15
K12$11,516,842 · 1
R01$11,506,820 · 5
U01$8,201,191 · 1
P30$1,608,954 · 2
T32$818,571 · 1
Top collaborators
- Anil K Sood11 shared
- Robert M. Chamberlain5 shared
- Razelle Kurzrock5 shared
- Anna E Lokshin5 shared
- Zhen Lu4 shared
- Steven J Skates3 shared
- Scott Kopetz1 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Yinhua Yu$1,384,292
- Ilya Shmulevich$15,034,675
Others in their field
Top investigators on “Malignant Neoplasm Of Ovary”
- David Heimbrook · Leidos Biomedical Research, Inc.$212,807,834
- Philip J Disaia · University Of California Irvine$127,836,851
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$32,228,202
- Larry Arthur$28,462,007
- Weiping Zou · University Of Michigan At Ann Arbor$24,295,958
- Norman Wolmark · Nsabp Foundation, Inc.$21,221,311
Research focus
Malignant Neoplasm Of OvaryWomanResearch PersonnelMalignant NeoplasmsUniversity Of Texas M D Anderson Cancer CenterClinical TrialsGrantProgramsBaseOvarianTumorLaboratoriesClinical ResearchBiological MarkersDiagnosisCancer CenterCancer CellChemotherapyPeer ReviewFacultyFundingCareerTranslational ResearchXenograft Procedure
Grant awards (147)
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer$1,993,287
P50 · FY2025 · CA
MD Anderson Cancer Center EDRN- Clinical Validation Center for Early Detection of Ovarian Cancer with a multiple marker algorithm$1,112,553
U01 · FY2025 · CA · contact PI
DIRAS3 disrupts K-RAS clustering and signaling, enhancing autophagy and response to autophagy inhibition$1,102,724
R01 · FY2025 · CA · contact PI
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer$273,112
P50 · FY2025 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer$177,085
P50 · FY2025 · CA
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer$177,085
P50 · FY2025 · CA · contact PI
Developmental Research Program$75,850
P50 · FY2025 · CA · contact PI
Career Enhancement Program$75,850
P50 · FY2025 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer$2,197,314
P50 · FY2024 · CA
MD Anderson Cancer Center EDRN- Clinical Validation Center for Early Detection of Ovarian Cancer with a multiple marker algorithm$823,867
U01 · FY2024 · CA · contact PI
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms$725,993
R01 · FY2024 · CA
DIRAS3 disrupts K-RAS clustering and signaling, enhancing autophagy and response to autophagy inhibition$538,502
R01 · FY2024 · CA · contact PI
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer$319,498
P50 · FY2024 · CA · contact PI
Targeting uterine serous carcinoma with antibody-drug conjugates$204,372
P50 · FY2024 · CA
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer$177,085
P50 · FY2024 · CA · contact PI
The SIK2 Inhibitor GRN-300 enhances PARP Inhibitor sensitivity and overcomes resistance by blocking homologous recombination (HR) DNA repair in ovarian cancer$177,085
P50 · FY2024 · CA
Developmental Research Program$81,388
P50 · FY2024 · CA · contact PI
Career Enhancement Program$81,388
P50 · FY2024 · CA · contact PI
The University of Texas MD Anderson Cancer Center SPORE in Ovarian Cancer$2,144,148
P50 · FY2023 · CA
MD Anderson Cancer Center EDRN- Clinical Validation Center for Early Detection of Ovarian Cancer with a multiple marker algorithm$1,014,275
U01 · FY2023 · CA · contact PI
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms$724,300
R01 · FY2023 · CA
DIRAS3 disrupts K-RAS clustering and signaling, enhancing autophagy and response to autophagy inhibition$667,020
R01 · FY2023 · CA · contact PI
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer$306,593
P50 · FY2023 · CA · contact PI
Developmental Research Program$85,150
P50 · FY2023 · CA · contact PI
Career Enhancement Program$85,150
P50 · FY2023 · CA · contact PI
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms$747,097
R01 · FY2022 · CA
Paul Calabresi Clinical Oncology Award$691,698
K12 · FY2022 · CA · contact PI
DIRAS3 disrupts K-RAS clustering and signaling, enhancing autophagy and response to autophagy inhibition$615,047
R01 · FY2022 · CA · contact PI
Leadership, Planning and Evaluation$146,474
P30 · FY2022 · CA · contact PI
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer$1,686,672
P50 · FY2021 · CA · contact PI
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms$777,101
R01 · FY2021 · CA
MD Anderson Cancer Center EDRN- CVC for Early Detection of Ovarian Cancer$521,230
U01 · FY2021 · CA · contact PI
Project 4: SIK2 PROVIDES A NOVEL TARGET FOR OVARIAN CANCER THERAPY IN COMBINATION WITH PACLITAXEL AND INHIBITORS OF PARP$316,529
P50 · FY2021 · CA · contact PI
Administrative Core$154,090
P50 · FY2021 · CA · contact PI
Leadership, Planning and Evaluation$146,474
P30 · FY2021 · CA · contact PI
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer$1,722,942
P50 · FY2020 · CA · contact PI
Development Funds$1,169,782
P30 · FY2020 · CA · contact PI
MD Anderson Cancer Center EDRN- CVC for Early Detection of Ovarian Cancer$1,003,814
U01 · FY2020 · CA · contact PI
Development of Novel Ovarian Cancer Biomarkers for Early Detection Algorithms$899,816
R01 · FY2020 · CA
Paul Calabresi Clinical Oncology Award$690,503
K12 · FY2020 · CA · contact PI
Project 4: SIK2 PROVIDES A NOVEL TARGET FOR OVARIAN CANCER THERAPY IN COMBINATION WITH PACLITAXEL AND INHIBITORS OF PARP$329,020
P50 · FY2020 · CA · contact PI
Administrative Core$154,348
P50 · FY2020 · CA · contact PI
Leadership, Planning and Evaluation$146,224
P30 · FY2020 · CA · contact PI
MD Anderson Cancer Center EDRN- CVC for Early Detection of Ovarian Cancer$973,698
U01 · FY2019 · CA · contact PI
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer$917,850
P50 · FY2019 · CA · contact PI
Paul Calabresi Clinical Oncology Award$801,143
K12 · FY2019 · CA · contact PI
ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer$368,600
R01 · FY2019 · CA · contact PI
Project 4: SIK2 PROVIDES A NOVEL TARGET FOR OVARIAN CANCER THERAPY IN COMBINATION WITH PACLITAXEL AND INHIBITORS OF PARP$228,384
P50 · FY2019 · CA · contact PI
ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer$124,136
R01 · FY2019 · CA · contact PI
Administrative Core$53,712
P50 · FY2019 · CA · contact PI
ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer$28,686
R01 · FY2019 · CA · contact PI
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer$1,813,624
P50 · FY2018 · CA · contact PI
MD Anderson Cancer Center EDRN- CVC for Early Detection of Ovarian Cancer$910,580
U01 · FY2018 · CA · contact PI
ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer$380,000
R01 · FY2018 · CA · contact PI
Project 4: SIK2 PROVIDES A NOVEL TARGET FOR OVARIAN CANCER THERAPY IN COMBINATION WITH PACLITAXEL AND INHIBITORS OF PARP$340,355
P50 · FY2018 · CA · contact PI
Paul Calabresi Clinical Oncology Award$202,024
K12 · FY2018 · CA · contact PI
Administrative Core$165,684
P50 · FY2018 · CA · contact PI
U.T. M. D. Anderson Cancer Center SPORE in Ovarian Cancer$1,732,856
P50 · FY2017 · CA · contact PI
MD Anderson Cancer Center EDRN- CVC for Early Detection of Ovarian Cancer$889,216
U01 · FY2017 · CA · contact PI
Paul Calabresi Clinical Oncology Award$801,143
K12 · FY2017 · CA · contact PI
ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer$380,000
R01 · FY2017 · CA · contact PI
Project 4: SIK2 PROVIDES A NOVEL TARGET FOR OVARIAN CANCER THERAPY IN COMBINATION WITH PACLITAXEL AND INHIBITORS OF PARP$338,337
P50 · FY2017 · CA · contact PI
Administrative Core$157,400
P50 · FY2017 · CA · contact PI
ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer$99,082
R01 · FY2017 · CA · contact PI
MD Anderson Cancer Center EDRN- CVC for Early Detection of Ovarian Cancer$951,958
U01 · FY2016 · CA · contact PI
Paul Calabresi Clinical Oncology Award$618,310
K12 · FY2016 · CA · contact PI
ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer$380,000
R01 · FY2016 · CA · contact PI
Supplement to CA135354 "ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer"$99,082
R01 · FY2016 · CA · contact PI
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer$901,656
P50 · FY2015 · CA · contact PI
ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer$380,000
R01 · FY2015 · CA · contact PI
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer$2,093,826
P50 · FY2014 · CA · contact PI
P1 - Early Detection of Epithelial Ovarian Cancer$894,806
P50 · FY2014 · CA · contact PI
Paul Calabresi Clinical Oncology Award$251,041
K12 · FY2014 · CA · contact PI
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer$2,082,690
P50 · FY2013 · CA · contact PI
Paul Calabresi Clinical Oncology Award$650,081
K12 · FY2013 · CA · contact PI
P1 - Early Detection of Epithelial Ovarian Cancer$278,231
P50 · FY2013 · CA · contact PI
Role of Macrophages in Resistance to Anti-VEGF Drugs in Ovarian Cancer$50,000
P50 · FY2013 · CA · contact PI
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer$50,000
P50 · FY2013 · CA · contact PI
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer$2,227,276
P50 · FY2012 · CA · contact PI
P1 - Early Detection of Epithelial Ovarian Cancer$864,877
P50 · FY2012 · CA · contact PI
Paul Calabresi Clinical Oncology Award$658,054
K12 · FY2012 · CA · contact PI
ARHI (DIRAS 3) in Autophagy and Dormancy of Ovarian Cancer$306,953
R01 · FY2012 · CA · contact PI
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer$2,117,925
P50 · FY2011 · CA · contact PI
P1 - Early Detection of Epithelial Ovarian Cancer$832,573
P50 · FY2011 · CA · contact PI
Paul Calabresi Clinical Oncology Award$649,162
K12 · FY2011 · CA · contact PI
ARHI (DIRAS 3) in Autophagy and Dormancy of Ovarian Cancer$306,953
R01 · FY2011 · CA · contact PI
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer$2,231,452
P50 · FY2010 · CA · contact PI
P1 - Early Detection of Epithelial Ovarian Cancer$917,914
P50 · FY2010 · CA · contact PI
Paul Calabresi Clinical Oncology Award$486,393
K12 · FY2010 · CA · contact PI
ARHI (DIRAS 3) in Autophagy and Dormancy of Ovarian Cancer$319,550
R01 · FY2010 · CA · contact PI
University of Texas MD Anderson SPORE in Ovarian Cancer$2,001,032
P50 · FY2009 · CA · contact PI
Early Detection of Epithelial Ovarian Cancer$414,975
P50 · FY2009 · CA · contact PI
Paul Calabresi Clinical Oncology Award$375,141
K12 · FY2009 · CA · contact PI
ARHI (DIRAS 3) in Autophagy and Dormancy of Ovarian Cancer$319,550
R01 · FY2009 · CA · contact PI
Career Development Program$177,919
P50 · FY2009 · CA · contact PI
Developmental Research Program$177,918
P50 · FY2009 · CA · contact PI
University of Texas MD Anderson SPORE in Ovarian Cancer$141,526
P50 · FY2009 · CA · contact PI
University of Texas MD Anderson SPORE in Ovarian Cancer$57,442
P50 · FY2009 · CA · contact PI
University of Texas MD Anderson SPORE in Ovarian Cancer$2,180,816
P50 · FY2008 · CA · contact PI
Paul Calabresi Clinical Oncology Award$545,376
K12 · FY2008 · CA · contact PI
Early Detection of Epithelial Ovarian Cancer$288,852
P50 · FY2008 · CA · contact PI
Career Development Program$123,789
P50 · FY2008 · CA · contact PI
Developmental Research Program$123,789
P50 · FY2008 · CA · contact PI
University of Texas MD Anderson SPORE in Ovarian Cancer$2,249,522
P50 · FY2007 · CA · contact PI
Paul Calabresi Clinical Oncology Award$188,979
K12 · FY2007 · CA · contact PI
University of Texas MD Anderson SPORE in Ovarian Cancer$2,252,567
P50 · FY2006 · CA · contact PI
Paul Calabresi Clinical Oncology Award$652,683
K12 · FY2006 · CA · contact PI
University of Texas MD Anderson SPORE in Ovarian Cancer$2,438,308
P50 · FY2005 · CA
Paul Calabresi Clinical Oncology Award$560,511
K12 · FY2005 · CA
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCER$1,150,000
P50 · FY2004 · CA
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM$538,920
K12 · FY2004 · CA
Specific Immunotherapy with Monoclonal Antibodies$249,000
R01 · FY2004 · CA
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCER$113,120
P50 · FY2004 · CA
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCER$2,376,677
P50 · FY2003 · CA
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM$538,920
K12 · FY2003 · CA
Specific Immunotherapy with Monoclonal Antibodies$249,000
R01 · FY2003 · CA
TRAINING FOR ACADEMIC ONCOLOGY$223,524
T32 · FY2003 · CA
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCER$2,331,840
P50 · FY2002 · CA
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM$538,920
K12 · FY2002 · CA
Specific Immunotherapy with Monoclonal Antibodies$249,000
R01 · FY2002 · CA
ARHI: AN IMPRINTED TUMOR SUPPRESSOR GENE$230,600
P01 · FY2002 · CA
TRAINING FOR ACADEMIC ONCOLOGY$216,851
T32 · FY2002 · CA
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCER$25,000
P50 · FY2002 · CA
Career development program$0
P50 · FY2002 · CA
CHEMOPREVENTION OF OVARIAN CANCER IN WOMEN USING FENRETINIDE/ORAL CONTRACEPTIVES$0
U19 · FY2002 · CA
Career development program$0
P50 · FY2002 · CA
Developmental research program$0
P50 · FY2002 · CA
Developmental research program$0
P50 · FY2002 · CA
Chemoprevention of ovarian cancer with fenretinide and oral contraceptives$0
P50 · FY2002 · CA
Chemoprevention of ovarian cancer with fenretinide and oral contraceptives$0
P50 · FY2002 · CA
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCER$2,028,681
P50 · FY2001 · CA
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM$538,920
K12 · FY2001 · CA
Specific Immunotherapy with Monoclonal Antibodies$249,000
R01 · FY2001 · CA
TRAINING FOR ACADEMIC ONCOLOGY$189,943
T32 · FY2001 · CA
Chemoprevention of ovarian cancer with fenretinide and oral contraceptives$0
P50 · FY2001 · CA
CHEMOPREVENTION OF OVARIAN CANCER IN WOMEN USING FENRETINIDE/ORAL CONTRACEPTIVES$0
U19 · FY2001 · CA
ARHI: AN IMPRINTED TUMOR SUPPRESSOR GENE$0
P01 · FY2001 · CA
Developmental research program$0
P50 · FY2001 · CA
Career development program$0
P50 · FY2001 · CA
UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCER$1,969,594
P50 · FY2000 · CA
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM$538,920
K12 · FY2000 · CA
Chemoprevention of ovarian cancer with fenretinide and oral contraceptives$533,563
P50 · FY2000 · CA
Y2, A NOVEL OVARIAN CANCER TUMOR SUPPRESSOR GENE$220,628
R01 · FY2000 · CA
CHEMOPREVENTION OF OVARIAN CANCER IN WOMEN USING FENRETINIDE/ORAL CONTRACEPTIVES$193,348
U19 · FY2000 · CA
TRAINING FOR ACADEMIC ONCOLOGY$188,253
T32 · FY2000 · CA
Career development program$150,000
P50 · FY2000 · CA
Developmental research program$150,000
P50 · FY2000 · CA